Lucid Diagnostics (LUCD) CMO reports 650K restricted shares and 100K options
Filing Impact
Filing Sentiment
Form Type
3/A
Rhea-AI Filing Summary
Lucid Diagnostics Inc. Chief Medical Officer Victoria Lee Tou-ho filed an amended Form 3 updating her equity holdings. She reports 650,000 shares of Common Stock, representing restricted stock granted under the company’s 2018 Equity Plan with specific future vesting dates.
The restricted stock comprises 200,000 shares granted on November 6, 2023 vesting November 6, 2026; 150,000 shares granted February 20, 2025 vesting May 20, 2028; and 300,000 shares granted February 20, 2026 vesting May 20, 2029, all subject to forfeiture if service requirements are not met. She also holds an employee stock option for 100,000 shares of Common Stock at an exercise price of $1.25 per share, expiring on February 22, 2034, with one-third already vested and the remainder vesting in equal quarterly installments through December 31, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Lee Victoria Tou-ho
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Employee stock option (right to buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Employee stock option (right to buy) — 100,000 shares (Direct, null);
Common Stock — 650,000 shares (Direct, null)
Footnotes (1)
- Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan with the following grant and vesting schedule: 200,000 (awarded November 6, 2023) that has a single vest date of November 6, 2026; 150,000 (awarded February 20, 2025) that has a single vest date of May 20, 2028; 300,000 (awarded February 20, 2026) that has a single vest date of May 20, 2029. Such restricted stock are subject to forfeiture if the requisite service period is not completed. One third of the option vested on December 31, 2024; the balance vests in eight equal quarterly installments, starting March 31, 2025 and ending on December 31, 2026.
Key Figures
Restricted Common Stock: 650,000 shares
Restricted grant 2023: 200,000 shares
Restricted grant 2025: 150,000 shares
+4 more
7 metrics
Restricted Common Stock
650,000 shares
Beneficial ownership reported on Form 3/A
Restricted grant 2023
200,000 shares
Granted Nov 6, 2023; single vest date Nov 6, 2026
Restricted grant 2025
150,000 shares
Granted Feb 20, 2025; single vest date May 20, 2028
Restricted grant 2026
300,000 shares
Granted Feb 20, 2026; single vest date May 20, 2029
Stock option underlying shares
100,000 shares
Employee stock option, underlying Common Stock
Option exercise price
$1.25 per share
Employee stock option (right to buy) exercise price
Option expiration
February 22, 2034
Employee stock option expiration date
Key Terms
restricted stock, 2018 Equity Plan, Employee stock option (right to buy), vesting, +1 more
5 terms
restricted stock financial
"Represents restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan"
Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.
2018 Equity Plan financial
"restricted stock granted to the reporting person under the Issuer's 2018 Equity Plan"
Employee stock option (right to buy) financial
"security_title": "Employee stock option (right to buy)""
vesting financial
"One third of the option vested on December 31, 2024; the balance vests in eight equal quarterly installments"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
forfeiture financial
"Such restricted stock are subject to forfeiture if the requisite service period is not completed"
FAQ
What does the Lucid Diagnostics (LUCD) Form 3/A filing report for Victoria Lee Tou-ho?
The Form 3/A shows Chief Medical Officer Victoria Lee Tou-ho’s current equity holdings, including 650,000 shares of restricted Common Stock and an employee stock option for 100,000 shares at $1.25 per share, providing transparency into her ownership stake and incentives.
What are the vesting terms of Victoria Lee Tou-ho’s restricted stock in Lucid Diagnostics (LUCD)?
Her restricted stock includes 200,000 shares vesting November 6, 2026, 150,000 shares vesting May 20, 2028, and 300,000 shares vesting May 20, 2029. All grants require continued service to avoid forfeiture, aligning compensation with long-term employment.
What stock options does Victoria Lee Tou-ho hold in Lucid Diagnostics (LUCD)?
She holds an employee stock option covering 100,000 shares of Common Stock at a $1.25 exercise price, expiring February 22, 2034. One third vested on December 31, 2024, with the remaining balance vesting in eight equal quarterly installments through December 31, 2026.
Does the Lucid Diagnostics (LUCD) Form 3/A show any recent insider buying or selling?
The Form 3/A reflects holdings rather than recent trades, with transactions categorized as holdings and transaction direction marked as unknown. It primarily details current restricted stock and option positions, not new open-market purchases or sales.